Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Clinical-stage biotechnology company developing combination therapies for cancer, focused on drug resistance and tumor relapse in solid tumors.
InxMed is a clinical-stage biotechnology company based in Nanjing, China, focused on developing innovative combination therapies for cancer, particularly targeting drug resistance and tumor relapse in solid tumors. The company applies a "tumor defense" framework, starting from fundamental cancer biology, to design treatments addressing underlying mechanisms of treatment failure. It has raised at least $65 million in total funding, including a $50 million Series B in March 2022 and a $15 million Series B+ in May 2022, with investors such as CS Capital, AIHC Fund, and Hyfinity Investments. Its team possesses extensive experience, having led over 100 clinical assets into clinics and more than 20 clinical development programs to NDA approval in China and the USA. InxMed was founded in late 2018 by Zaiqi Wang.
InxMed has raised $84.0M across 3 funding rounds.
InxMed has raised $84.0M in total across 3 funding rounds.
InxMed has raised $84.0M across 3 funding rounds. Most recently, it raised $15.0M Series B in May 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 9, 2022 | $15M Series B | DR. Sylvia XIN HE | — | Announced |
| Mar 4, 2022 | $50M Series B | HUA YI | Aihc Capital, Growth Fund, Hosencare Fund | Announced |
| Sep 4, 2020 | $19M Series A | China Growth Capital | Grand Yangtze Capital | Announced |
InxMed has raised $84.0M in total across 3 funding rounds.
InxMed's investors include Dr. Sylvia Xin He, Hua Yi, AIHC Capital, Growth Fund, Hosencare Fund, China Growth Capital, Grand Yangtze Capital.